A proven pioneer in medical technology and recognized expert in physiological signal analysis, Marek has played a pivotal role as Solvemed's CTO. His transition to the Board marks a strategic inflection point as the company scales its AI Pupillometry System toward broader clinical adoption.
%20(1)%20(1).png)
Marek’s entrepreneurial and scientific path has unfolded over more than twenty years, shaped by work that blends clinical insight with applied data science and device engineering. As the founder of Medicalgorithmics S.A., he guided the development of PocketECG, a real-time ambulatory cardiac monitoring system that gave clinicians new visibility into complex arrhythmias. The platform changed how long-term cardiac rhythm analysis could be performed by delivering continuous, high-fidelity data rather than intermittent snapshots.
The experience of building diagnostics and predictive algorithms from physiological signals now anchors his work at Solvemed, where those same principles are being applied to neurological diagnostics. His current focus is advancing Solvemed’s AI Pupillometry System, which turns subtle variations in the pupillary light reflex into reliable, clinically meaningful information for rapid neurological assessment.
At Solvemed, Marek has shaped a technology stack designed to bring precision and consistency to neurological evaluation. The company’s AI Pupillometry System captures and analyzes the pupillary light reflex in quantitative form, allowing clinicians to interpret neurological status with a level of objectivity that traditional methods cannot offer. The system operates reliably across different lighting conditions by applying adaptive computer vision and machine learning models to each measurement. It then translates those measurements into standardized data that can be integrated directly into hospital records, enabling care teams to track changes over time and collaborate around a shared clinical picture.
The platform supports continuous use in high acuity environments, including intensive care units, emergency departments, transport teams, and outpatient neurology. In these settings, it gives clinicians a non-invasive window into brain function and can contribute to earlier recognition of deterioration or injury at moments when a faster response can influence outcomes.
Marek’s role extends beyond product development and into the creation of clinical partnerships that validate the system in real-world care. Solvemed is working with large US health systems to evaluate the performance of AI-driven pupillometry in scenarios such as suspected traumatic brain injury, stroke, hypoxic events, and other acute neurological presentations. These collaborations are already surfacing evidence that high-resolution pupil dynamics can reveal early patterns of decline that conventional penlight checks fail to detect.
By capturing responses that are too small or too fast for the human eye to register, the platform is allowing clinicians to intervene with greater confidence. For patients, this means evaluations that are more consistent, decisions that are better informed, and a higher chance that neurological deterioration is recognized while it is still reversible.
We're thrilled to welcome Marek to our Board of Directors. His scientific rigor, commercial insight, and commitment to evidence-based innovation will be instrumental as we pursue our mission to revolutionize brain health assessment through AI-powered quantitative pupillometry.
.png)
%20(1).png)